Gene therapy approaches to Parkinson's disease: Preclinical to clinical trials, or what steps to take to get there from here?

Experimental Neurology

Volumn 144, Issue 1, 1997, Pages 160-167

  Redmond Jr , D Eugene ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; GENE THERAPY; MONKEY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL;

EID: 0031106276     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1996.6403     Document Type: Article

References (72)

1. 1. AEBISCHER, P., M. SCHLUEP, N. DEGLON, J. M. JOSEPH, L. HIRT, B. HEYD, M. GODDARD, J. P. HAMMANG, A. D. ZURN, A. C. KATO, F. REGLI, AND E. E. BAETGE. 1996. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nat. Med. 2: 696-699.
2. 2. AXELROD, J., AND R. WEINSHILBOUM. 1972. Catecholamines. N. Engl. J. Med. 287: 237-242. [Review]
3. 3. BACKLUND, E. O., B. GRANBERG, E. HAMBERGER, A. KNUTSSON, G. MÅRTENSSON, G. SEDVALL, et al. 1985. Transplantation of adrenal medullary tissue to striatum in parkinsonism: First clinical trials. J. Neurosurg. 62: 169-173.
4. 4. BAKAY, R. A. E., D. L. BARROW, M. S. FIANDACA, P. M. IUVONE, A. SCHIFF, AND D. C. COLLINS. 1987. Biochemical and behavioral correction of MPTP Parkinson-like syndrome by fetal cell transplantation. Ann. N. Y. Acad. Sci. 495: 623-640.
5. 5. BANKIEWICZ, K. S., R. J. PLUNKETT, I. MEFFORD, I. J. KOPIN, AND E. H. OLDFIELD. 1990. Behavioral recovery from MPTP-induced parkinsonism in monkeys after intracerebral tissue implants is not related to CSF concentrations of dopamine metabolites. Prog. Brain Res. 82: 561-571.
6. 6. BERNHEIMER, H., W. BIRKMAYER, O. HORNYKIEWICZ, K. JELLINGER, AND F. SEITELBERGER 1973. Brain dopamine and the syndromes of Parkinson and Huntington: Clinical, morphological and neurochemical correlations. J. Neurosci. 20: 415-4155.
7. 7. BJÖRKLUND, A., AND U. STENEVI. 1979. Reconstruction of the nigrostriatal dopamine pathway by intracerebral nigral transplants. Brain Res. 177: 555-560.
8. 8. BRUNDIN, P., R. E. STRECKER, O. LINDVALL, O. ISACSON, O. G. NILSSON, G. BARBIN, et al. 1987. Intracerebral grafting of dopamine neurons: Experimental basis for clinical trials in patients with Parkinson's disease. Ann. N. Y. Acad. Sci. 495: 473-496.
9. 9. BURNS, R. S., C. C. CHIUEH, S. P. MARKEY, M. H. EBERT, D. M. JACOBOWITZ, AND I. J. KOPIN. 1983. Aprimate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Nat. Acad. Sci. USA 80: 4546-4550.
10. 10. COMMITTEE, C., J. W. LANGSTON, H. WIDNER, C. G. GOETZ, D. BROOKS, S. FAHN, T. FREEMAN, AND R. WATTS. 1992. Core Assessment Program for Intracerebral Transplantations (CAPIT). Mov. Disord. 7: 2-13.
11. 11. COTZIAS, G. C., M. H. VAN WOERT, AND L. M. SCHIFFER. 1967. Aromatic amino acids and modification of parkinsonism. N. Engl. J. Med. 276: 374-379.
12. 12. DEUTCH, A. Y., J. D. ELSWORTH, M. GOLDSTEIN, K. FUXE, D. E. REDMOND, JR., J. R. SLADEK, JR., AND R. H. ROTH. 1986. Preferential vulnerability of A8 dopamine neurons in the primate to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neurosci. Lett. 68: 51-56.
13. 13. DUNN, E. H. 1917. Primary and secondary findings in a series of attempts to transplant cerebral cortex in the albino rat. J. Comp. Neurol. 27: 565-582.
14. 14. DURING, M. J., M. G. KAPLITT, JR., P. LEONE, X. XIAO, J. D. ELSWORTH, R. H. ROTH, J. R. SLADEK, JR., D. E. REDMOND, JR., AND K. L. O'MALLEY. 1994. AAV-mediated transfer of tyrosine hydroxylase and aromatic amino acid decarboxylase genes into the primate brain: A direct gene therapy approach to Parkinson's disease. Neurosci. Abstr. 20: 1465.
15. 15. ELSWORTH, J. D., M. D. AL-TIKRITI, J. R. SLADEK, JR., J. R. TAYLOR, R. B. INNIS, D. E. REDMOND, JR., AND R. H. ROTH. 1994. Novel radioligands for the dopamine transporter demonstrate the presence of intrastriatal nigral grafts in the MPTP-treated monkey: Correlation with improved behavioral function. Exp. Neurol. 126: 300-304.
16. 16. ELSWORTH, J. D., A. Y. DEUTCH, D. E. REDMOND, JR., J. R. SLADEK, AND R. H. ROTH. 1987. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on catecholamines and metabolites in primate brain and CSF. Brain Res. 415: 293-299.
17. 17. ELSWORTH, J. D., A. Y. DEUTCH, D. E. REDMOND, JR., J. R. SLADEK, JR., AND R. H. ROTH. 1990. MPTP reduces dopamine and norepinephrine concentrations in the supplementary motor area and cingulate cortex of the primate. Neurosci. Lett. 114: 316-322.
18. 18. ELSWORTH, J. D., A. Y. DEUTCH, D. E. REDMOND, JR., J. R. TAYLOR, J. R. SLADEK, JR., AND R. H. ROTH. 1989. Symptomatic and asymptomatic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated primates: Biochemical changes in striatal regions. Neuroscience 33: 323-331.
19. 19. ELSWORTH, J. D., D. J. LEAHY, R. H. ROTH, AND D. E. REDMOND, JR. 1987. Homovanillic acid concentrations in brain, CSF and plasma as indicators of central dopamine function in primates. J. Neurol Transm. 68: 51-62.
20. 20. ELSWORTH, J. D., J. R. TAYLOR, P. BERGER, AND R. H. ROTH. 1993. Cocaine-sensitive and -insensitive dopamine uptake in prefrontal cortex, nucleus accumbens, and striatum. Neurochem. Int. 23:61-69.
21. 21. EPSTEIN, S. 1991. Regulatory concerns in human gene therapy. Hum. Gene Ther. 2: 243-249.
22. 22. FAHN, S., R. ELTON, AND MEMBERS OF THE UPDRS DEVELOPMENT COMMITTEE. 1987. Unified Parkinson's disease rating scale. Pages 153-163 in S. Fahn, C. Marsden, M. Goldstein, and C. Calne, Eds., Recent Developments in Parkinson's Disease. Macmillan, Florham Park, NJ.
23. 23. FOOD AND DRUG ADMINISTRATION. 1993. Application of current statutory authorities to human somatic cell therapy products and gene therapy products. Pages 53248-53251 in C. F. B. E. A. Research, Ed., Vol. 58. Food and Drug Administration, Rockville, MD.
24. 24. FOOD AND DRUG ADMINISTRATION. 1996. Addendum to the points to consider in human somatic cell therapy and gene therapy. Pages 2-18 in C. F. B. E. A. Research, Ed. Congressional, Consumer and International Affairs Staff (HFB-142), Rockville, MD.
25. 25. FORNO, L. S., L. E. DELANNEY, I. IRWIN, AND J. W. LANGSTON. 1986. Neuropathology of MPTP-treated monkeys: Comparison with the neuropathology of human idiopathic Parkinson's disease. Pages 119-140 in S. P. Markey, Ed., MPTP: A Neurotoxin Producing a Parkinsonian Syndrome. Academic Press, Orlando.
26. 26. FORNO, L. S., L. E. DELANNEY, I. IRWIN, AND J. W. LANGSTON. 1993. Similarities and differences between MPTP-induced parkinsonism and Parkinson's disease: Neuropathologic considerations. Adv. Neurol. 60: 600-608.
27. 27. FREED, C. R., R. E. BREEZE, N. L. ROSENBERG, S. A. SCHNECK, E. KRIEK, J. X. QI, T. LONE, Y. B. ZHANG, J. A. SNYDER, T. H. WELLS, et al. 1992. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease [see comments]. N. Engl. J. Med. 327: 1549-1555.
28. 28. FREED, C. R., R. E. BREEZE, N. L. ROSENBERG, S. A. SCHNECK, T. H. WELLS, J. N. BARRETT, S. T. GRAFTON, J. C. MAZZIOTTA, D. EIDELBERG, AND D. A. ROTTENBERG. 1990. Therapeutic effects of human fetal dopamine cells transplanted in a patient with Parkinson's disease. Prog. Brain Res. 82: 715-721.
29. 29. FREED, W. J. 1990. Fetal brain grafts and Parkinson's disease. Science 250: 1434.
30. 30. FREED, W. J. 1991. Substantia nigra grafts and Parkinson's disease: From animal experiments to human therapeutic trials. Restor. Neurol. Neurosci. 3: 109-134.
31. 31. FREED, W. J. 1993. Neural transplantation: Prospects for clinical use. Cell Transplant. 2: 13-31.
32. 32. FREED, W. J., M. J. PERLOW, F. KAROUIM, A. SEIGER, L. OLSON, B. J. HOFFER, AND R. J. WYATT. 1980. Restoration of dopaminergic function by grafting of fetal rat substantia nigra to the caudate nucleus: Long-term behavioral, biochemical and histochemical studies. Ann. Neurol. 8: 510-519.
33. 33. FREED, W. J., M. POLTORAK, AND J. B. BECKER. 1990. Intracerebral adrenal medulla grafts: A review. Exp. Neurol. 110: 139-166.
34. 34. FRISON, L., AND S. J. POCOCK. 1992. Repeated measures in clinical trials: Analysis using mean summary statistics and its implications for design. Stat. Med. 11: 1685-1704.
35. 35. GAGE, F. H. 1990. Intracerebral grafting of genetically modified cells acting as biological pumps. Trends Pharmacol. Sci. 11: 437-439.
36. 36. GAGE, F. H., L. J. FISHER, H. A. JINNAH, M. B. ROSENBERG, M. H. TUSZYNSKI, AND T. FRIEDMANN. 1990. Grafting genetically modified cells to the brain: Conceptual and technical issues. Prog. Brain Res. 82: 1-10. [Review]
37. 37. GOETZ, C. G., C. W. OLANOW, W. C. KOLLER, R. D. PENN, D. CAHILL, R. MORANTZ, G. STEBBINS, C. M. TANNER, H. L. KLAWANS, K. M. SHANNON, C. L. COMELLA, T. WITT, C. COX, M. WAXMAN, AND L. GAUGER. 1989. Multicenter study of autologous adrenal medullary transplantation to the corpus striatum in patients with advanced Parkinson's disease. N. Engl. J. Med. 320: 337-342.
38. 38. GUNTER, K. C., A. S. KHAN, AND P. D. NOGUCHI. 1993. The safety of retroviral vectors. Hum. Gene Ther. 4: 643-645.
39. 39. HOEHN, M. M., AND M. D. YAHR 1967. Parkinsonism: Onset, progression, and mortality. Neurology 17: 427-442.
40. 40. HOFFER, B. J., AND L. OLSON. 1991. Ethical issues in brain-cell transplantation. Trends Neurosci. 14: 384-388.
41. 41. HORNYKIEWICZ, O. 1982. Brain neurotransmitter changes in Parkinson's disease. Pages 41-58 in D. Marsden and S. Fahn, Eds., Movement Disorders. Butterworth, London.
42. 42. IACONO, R. P., Z. S. TANG, J. C. MAZZIOTTA, S. GRAFTON, AND M. HOEHN. 1992. Bilateral fetal grafts for Parkinson's disease: 22 months' results. Stereotact. Funct. Neurosurg. 58: 84-87.
43. 43. INNIS, R. B., J. P. SEIBYL, B. E. SCANLEY, M. LARUELLE, A. ABI-DARGHAM, E. WALLACE, R. M. BALDWIN, Y. ZEA-PONCE, S. ZOGHBI, S. WANG, et al. 1993. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc. Natl. Acad. Sci. USA 90: 11965-11969.
44. 44. KESSLER, D. A., J. P. SIEGAL, P. D. NOGUCHI, K. C. ZOON, K. L. FEIDEN, AND J. WOODCOCK. 1993. Regulation of somatic-cell therapy and gene therapy by the Food and Drug Administration. N. Engl. J. Med. 329: 1169-1173.
45. 45. LANGSTON, J. W., P. BALLARD, J. W. TETRUD, AND I. IRWIN. 1983. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 979-980.
46. 123I]-b-CIT: Pharmacological characterization of brain uptake in nonhuman primates. Synapse 13: 295-309.
47. 47. LINDVALL, O., S. REHNCRONA, P. BRUNDIN, B. GUSTAVII, B. ASTEDT, H. WIDNER, et al. 1989. Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease: A detailed account of methodology and a 6-month follow-up. Arch. Neurol. 46: 615-631.
48. 48. LINDVALL, O., H. WIDNER, S. REHNCRONA, P. BRUNDIN, P. ODIN, B. GUSTAVII, R. FRACKOWIAK, K. L. LEENDERS, G. SAWLE, J. C. ROTHWELL, A. BJÖRKLUND, AND C. D. MARSDEN. 1992. Transplantation of fetal dopamine neurons in Parkinson's disease: One-year clinical and neurophysiological observations in two patients with putaminal implants. Ann. Neurol. 31: 155-165.
49. 49. MADRAZO, I., R. DRUCKER-COLIN, V. DIAZ, J. MARTINEZ-MATA, C. TORRES, AND J. J. BECERRIL. 1987. Open microsurgical autograft of adrenal medulla to the right caudate nucleus in two patients with intractable Parkinson's disease. N. Engl. J. Med. 316: 831-834.
50. 50. MAHOWALD, M. B., J. AREEN, B. J. HOFFER, A. R. JONSEN, P. KING, J. SILVER, et al. 1987. Transplantation of neural tissue from fetuses. Science 235: 1307-1308.
51. 51. MORIHISA, J. M., R. K. NAKAMURA, W. J. FREED, M. MISHKIN, AND R. J. WYATT. 1984. Adrenal medulla grafts survive and exhibit catecholamine-specific fluorescence in the primate brain. Exp. Neurol. 84: 643-653.
52. 52. MORSE COLLEGE DIVINITY SCHOOL AND THE SCHOOL OF MEDICINE OF YALE UNIVERSITY. A symposium: Embryonic brain cell transplantation for the treatment of central nervous system disorders: ethical issues and questions. Morse College, New Haven, CT, February 26, 1987.
53. 123I]-2β-Carbomethoxy-3β-(4-iodophenyl) tropane: High-affinity SPECT radiotracer of monoamine reuptake sites in brain. J. Med. Chem. 34: 3144-3146.
54. 54. OLANOW, C. W., W. KOLLER, C. G. GOETZ, G. T. STEBBINS, D. W. CAHILL, L. L. GAUGER, R. MORANTZ, R. D. PENN, C. M. TANNER, H. L. KLAWANS, K. M. SHANNON, C. L. COMELLA, AND T. WITTE. 1990. Autologous transplantation of adrenal medulla in Parkinson's disease. Arch. Neurol. 47: 1286-1289.
55. 55. ORKIN, S. H., A. G. MOTULSKY, AND CO-CHAIRS. 1995. Report and recommendations of the panel to assess the NIH investment in research on gene therapy. NIH Web Page.
56. 56. PERLOW, M. J., W. J. FREED, B. J. HOFFER, A. SEIGER, L. OLSON, AND R. J. WYATT. 1979. Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system. Science 204: 643-653.
57. 57. REDMOND, D. E., JR., B. J. HOFFER, et al. 1992. IVth International Symposium on Neural Transplantation transcript of the closing discussion. J. Neural Transplant. Plast. 4: 113-125.
58. 58. REDMOND, D. E., JR., K. L. O'MALLEY, M. J. KAPLITT, R. J. SAMULSKI, J. D. ELSWORTH, J. R. SLADEK, JR., P. LEONE, X. XIAO, A. FREESE, J. R. TAYLOR, R. H. ROTH, AND M. J. DURING. 1995. AAV vectored gene therapy in primate Parkinsons model. Soc. Neurosci. Abstr. 21: 540.
59. 59. REDMOND, D. E., JR., R. J. ROBBINS, F. NAFTOLIN, K. L. MAREK, T. VOLLMER, C. LERANTH, R. H. ROTH, L. H. PRICE, A. GJEDDE, B. S. BUNNEY, K. J. SASS, J. D. ELSWORTH, L. E. KIER, R. MAKUCH, P. B. HOFFER, B. I. GULANSKI, C. SERRANO, AND D. D. SPENCER. 1993. Cellular replacement of dopamine deficit in Parkinson's disease using human fetal mesencephalic tissue: Preliminary results in four patients. Pages 325-359 in S. G. Waxman, Ed., Molecular and Cellular Approaches to the Treatment of Neurological Disease. Raven Press, New York.
60. 60. REDMOND, D. E., JR., E. SMITH, R. H. ROTH, J. D. ELSWORTH, J. R. TAYLOR, J. R. SLADEK, R. B. INNIS, J. P. SEIBYL, AND P. HOFFER 1993. SPECT studies with β-CIT dopamine grafts. Neurosci. Abstr.
61. 61. REDMOND, D. E., JR., J. R. SLADEK, JR., R. H. ROTH, T. J. COLLIER, J. D. ELSWORTH, A. Y. DEUTCH, AND S. HABER 1986. Fetal neuronal grafts in monkeys given methylphenyltetrahydropyridine. Lancet 1: 1125-1127.
62. 18F]6-L-fluorodopa studies in two patients with putaminal implants. Ann. Neurol. 31: 166-173.
63. 63. SHAYA, E., U. SCHEFFEL, R. DANNALS, G. RICAURTE, F. CARROL, H. WAGNER, JR., AND D. WONG. 1992. In vivo imaging of dopamine reuptake sites in the primate brain using single photon emission computed tomography (SPECT) and iodin-123 labeled RTI-55. Synapse 10: 169-172.
64. 64. SHORT, M. P., M. B. ROSENBERG, Z. D. EZZEDINE, F. H. GAGE, T. FRIEDMANN, AND X. O. BREAKEFIELD. 1990. Autocrine differentiation of PC12 cells mediated by retroviral vectors. Dev. Neurosci. 12: 34-45.
65. 65. SLADEK, J. R., JR., T. J. COLLIER, S. N. HABER, R. H. ROTH, AND D. E. REDMOND, JR. 1986. Survival and growth of fetal catecholamine neurons transplanted into primate brain. Brain Res. Bull. 17: 809-818.
66. 66. SPENCER, D. D., R. J. ROBBINS, F. NAFTOLIN, K. L. MAREK, T. VOLLMER, C. LERANTH, R. H. ROTH, L. H. PRICE, A. GJEDDE, B. S. BUNNEY, K. J. SASS, J. D. ELSWORTH, L. E. KIER, R. MAKUCH, P. B. HOFFER, AND D. E. REDMOND, JR. 1992. Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of Parkinsonian patients: Functional effects for 18 months. N. Engl. J. Med. 327: 1541-1548.
67. 67. TAYLOR, J. R., J. D. ELSWORTH, R. H. ROTH, T. J. COLLIER, J. R. SLADEK, AND D. E. REDMOND, JR. 1990. Improvements in MPTP-induced object retrieval deficits and behavioral deficits after fetal nigral grafting in monkeys. Pages 543-559 in S. J. Richards and S. B. Dunnett, Eds., Progress in Brain Research, Vol. 82. Elsevier, Amsterdam.
68. 68. TAYLOR, J. R., J. D. ELSWORTH, J. R. SLADEK, JR., R. H. ROTH, AND D. E. REDMOND, JR. 1994. Behavioral effects of MPTP administration in the vervet monkey: A primate model of Parkinson's disease. Pages 139-174 in M. L. Woodruff and A. J. Nonneman, Eds., Toxin-Induced Models of Neurological Disorders. Plenum Press, New York.
69. 69. U.S. CONGRESS, O. O. T. A. 1990. Neural Grafting: Repairing the Brain and Spinal Cord. U.S. Gov. Printing Office, Washington, DC.
70. 70. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH. 1988. Report of the Human Fetal Tissue Transplantation Research Panel. U.S. Gov. Printing Office, Public Health Service, Washington, DC.
71. 71. WIDNER, H. 1994. NIH neural transplantation funding [letter]. Science 263: 737.
72. 72. WIDNER, H., J. TETRUD, S. REHNCRONA, B. SNOW, P. BRUNDIN, B. GUSTAVII, A. BJÖRKLUND, O. LINDVALL, AND J. W. LANGSTON. 1992. Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). N. Engl. J. Med. 327: 1556-1563.